Vertex Pharmaceuticals Incorporated VRTX NASDAQ

Vertex Pharmaceuticals Incorporated (VRTX) generated $3.63B in operating cash flow for fiscal year 2025. After capital expenditures of $437.6M, free cash flow was $3.19B.

Free cash flow margin was 26.5% of revenue. Cash conversion ratio was 0.92x, suggesting some earnings are non-cash.

The company returned $2.02B in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (81/100, Pass) — $3.19B (26.5% FCF margin) supports a durable competitive advantage
• INCOME (100/100) — Cash conversion ratio was 0.92x suggests some earnings are non-cash items

Overall SharesGrow Score: 84/100 with 5/7 criteria passed.